Pliant Therapeutics, Inc. (PLRX)

Market Cap	86.55M
Revenue (ttm)	n/a
Net Income (ttm)	-219.52M
Shares Out	61.39M
EPS (ttm)	-3.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	581,363
Open	1.370
Previous Close	1.400
Day's Range	1.350 - 1.425
52-Week Range	1.100 - 16.100
Beta	1.31
Analysts	Hold
Price Target	9.79 (+594.33%)
Earnings Date	Aug 6, 2025

About PLRX

Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company’s lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of αvß6 and αvß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of αvß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibi...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 3, 2020
• Employees: 171
• Stock Exchange: NASDAQ
• Ticker Symbol: PLRX
• Website: https://pliantrx.com

Analyst Summary

According to 10 analysts, the average rating for PLRX stock is "Hold." The 12-month stock price target is $9.79, which is an increase of 594.33% from the latest price.

Price Target

$9.79

(594.33% upside)

Analyst Consensus: Hold